Volume 24, Number 10—October 2018
CME ACTIVITY - Synopsis
Human Pegivirus in Patients with Encephalitis of Unclear Etiology, Poland
Table 1
Characteristic | Encephalitis patients infected with pegivirus |
Other encephalitis patients |
||||
---|---|---|---|---|---|---|
Patient 1 | Patient 2 | Patient 3 | Infectious cause identified, n = 41† | Unknown cause or autoimmune illness, n = 52‡ | ||
Male sex | No | No | Yes | 30 (73) | 23 (44) | |
Median age, y (range) | 55 | 28 | 20 | 38 (19–85) | 38 (20–82) | |
Pharmacological immunosuppression present | 0 | 0 | 0 | 2 (5) | 3 (6) | |
HIV positive | 0 | 0 | 0 | 0 | 2 (4) | |
Cancer | 0 | 0 | 0 | 6 (15) | 1 (2) | |
Median length of hospital stay, d (range) | 41 | 30 | 8 | 12 (5–97) | 11.5 (6–79) | |
Fever >38°C | Yes | Yes | No | 26 (63) | 18 (35) | |
Headache | Yes | Yes | No | 22 (54) | 25 (48) | |
Altered mental status | Yes | Yes | No | 36 (88) | 47 (85) | |
Focal neurologic signs | No | No | Yes | 9 (22) | 10 (20) | |
Seizures | No | No | Yes | 12 (29) | 16 (31) | |
Stiff neck |
No |
No |
No |
7 (17) |
12 (23) |
|
CSF analysis | ||||||
Median leukocyte count, cells/mm2 (range) | 3 | 4 | 3 | 41 (1–1225) | 18 (1–362) | |
Median protein level, g/L (range) |
0.68 |
0.26 |
1.63 |
0.57 (0.16–3.21) |
0.56 (0.11–3.33) |
|
Death | 0 | 0 | 0 | 1 (2.4) | 0 |
*Values are no. (%) unless otherwise indicated. CSF, cerebrospinal fluid
†Identified infections were human herpesvirus 1 (n = 22), enterovirus (n = 6), varicella zoster virus (n = 5), tick-borne encephalitis virus (n = 6), and cytomegalovirus (n = 2).
‡All markers of viral infection were negative, but 5 patients had antibodies against N-methyl-D-aspartate receptor and a diagnosis of autoimmune encephalitis.
Page created: September 14, 2018
Page updated: September 14, 2018
Page reviewed: September 14, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.